Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Neuropace Inc logo
NPCE

Neuropace Inc

MaveScore 26 Low model confidence
Last Price US$15.34 As of Jun 15, 2026
Market Cap US$559.0m Company size context
7D Performance -1.86% Past 7 days
1Y Performance 21.26% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Dec 31, 2025

167 days old

Market price date

Jun 15, 2026

1 day old

Coverage

16/16

No missing model inputs

Data quality

Excellent

Current stored snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 26 Low confidence

Stored data quality

Freshness and coverage checks

Latest stored fundamentals and price inputs are recent enough for normal research review.

16/16 Current stored snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

13/35 Weak

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

6/25 Weak

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

0/15 Weak

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

6/15 Weak

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

1/10 Weak

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
  • Financial strength rewards durable profitability, margins, and positive free cash flow.
  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Dashboard Funda..tals Deep..lue Prediction Screener Map

Neuropace Inc Overview

Industry: Medical Devices

Sector: Healthcare

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Neuropace Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review Neuropace Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



Neuropace Inc Competitors

Neuropace Inc operates in the Medical Devices industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

Neuropace Inc

US$15.34

US$559.0m

-1.86%

21.26%